The common 677C->T mutation ( + ) in the 5,10-methylenetetrahydrofolate reductase gene, resulting in decreased activity of the enzyme, has been associated with spina bifida neural tube defects (NTD). We combined all known Dutch control groups, a total of 1273 individuals, and found a prevalence of the 677C-+T mutation of 8.4% . When compared with the frequencies in 55 SB patients and to mothers with a child with SB their parents, this gave an OR of 1.9 [95% Cl 1*1 -3.3] for mothers and an OR of 1.5 [95% Cl 0.74-3.1] for patients. The frequency of this mutation and its associated risk for NTD may be population-dependent However, the frequencies of the 677C->T mutation in different national and international control groups are almost all in the same range. We therefore combined the observed frequencies of the 677C-*T mutation in all reported studies. The mutation was present in 9.2% of controls, resulting in ORs for all reported NTD patients and their parents of: 1.7 [95% Cl: 1.1-2,6]; 1.8 [95% Cl: 1.1-3.1] and 1.9 [95% Cl: 1.3-2.8] for mothers (combined preval ence 14.5%), fathers (combined prevalence 15.5%) and NTD patients (combined prevalence 16.4%), respectively, vs, all international controls. This meta analysis confirms that the 677C-*T mutation is a genetic risk factor for NTD.
Introduction
In our previous studies, a common 677C->T muta tion in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene, resulting in reduced enzyme activity and an impaired homocysteine/folate metabolism, was investigated as a genetic risk factor for spina bifida (SB).1'2 Homozygosity for the alanine to valine substitution ( + /+ ) was observed in 4.8% of the controls, vs. 15.7% of the mothers, 10.0% of the fathers and 12.7% of the affected children of the families with SB offspring.1 Significant odds ratios (ORs) of 3,7 for mothers and 2.9 for SB patients were observed in the first study, demonstrating an abnormality in folate metabolism as a genetic risk factor for SB. O ur findings have been confirmed by two other studies on neural tube defects (NTD).3'4 Recently, we showed that the O R increased to 4.1 [95% Cl 1.5-11.1] if the mother has a + / + genotype and her child a + /-genotype, and even to 6.1 [95% Cl 1.0-35.5] if both the mother and her child have a + /+ genotype. 2 MTHFR catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a 
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cosubstrate for the remethylation of homocysteine to methionine. The 6 7 7 C^T mutation causes reduced MTHFR activity and a protein with thermoiabile properties and is associated with elevated plasma homocysteine levels and a redistribution of folates, namely elevated red-cell folate (RCF) and lowered plasma folate.1'2 This mutation explains a substantial part of the observed elevated plasma homocysteine levels in mothers of children with NTD. Although mean homocysteine levels were increased in those homozygous for this mutation, not all + /+ subjects had elevated homocysteine levels. Plasma folate is a very strong determinant of plasma homocysteine in individuals with the + /+ genotype. It has been suggested that individuals who are homozygous for the 677C-*T mutation in the MTHFR gene have higher nutritional folate requirements.2 W e reported previously that about 5% of the Dutch control group had the mutation in the hom ozy gous form,1 whereas an Irish study observed a frequency of 6,1% and an Atlanta group a frequency of 5% in their controls.3,4 However, the prevalence of homozygosity for this mutation is also reported to be 12% in French Canadians,5 16,3% in Italians/ 10.7% in W hite Australians/ and (12% among British controls, 2% in Japanese and 9% in Utah Mormons). 8 In this study, we examined whether these reported prevalences of the 677C~>T mutation in the MTHFR gene are population-dependent. If they were, the risk of NTD associated with this mutation might also be population-dependent All known Dutch control groups were combined to estimate the prevalence of the 677C->T mutation in the Dutch population.
Furthermore, all published data of control groups and NTD families were pooled to study the im plica tions of this common mutation for the risk of NTD.
Methods
SB patients and their parents were recruited in collaboration with the Dutch society for patients with central nervous system defects and their parents (BOSK).1 The study group consisted, as reported previously,1,2 of 70 mothers, 60 fathers and 55 children with SB, Children younger than 3 years were excluded.
For a more reliable estimate of the prevalence of the 677C ->T mutation among the Dutch population, the control group was composed of controls from several published and unpublished Dutch studies. Some 440 controls were from published studies: 318 controls (207 and 109 of whom had been used in our previous studies);1,9 99 controls10 and 23 con trols,11 and 833 as yet unpublished controls. All the mutation analyses were performed by our laboratory. By com bining these different studies, we obtained a large control group of 1273 unrelated Dutch indi viduals of both sexes with no history of NTD.
The investigated mutation in the MTHFR gene is a C to T substitution at base pair 677, altering an alanine to a valine residue. The prevalence of this mutation was investigated, as reported before.1
Statistics
Crude odds ratios (OR) and 95% confidence intervals (95% CIs) were calculated to estimate the relative risk of the 677C ->T mutation for NTD offspring.
Results
O f 1273 Dutch controls, 107 (8.4%; 95% Cl 6.9%-10.0%) had a + /+ genotype for the 677C-+T mutation ( Table 1 ). The + /-genotype was observed in 537 and the genotype in 629 control. The observed frequency of the + allele was 0.3. Figure 1 shows the frequencies and 95% CIs of the 677C-+T mutation among the different Dutch controls and other international studies. Since there were no significant differences between the Dutch control groups, they were combined into one total Dutch control group. A large international control group was con structed by com bining Dutch and other reported control groups.1-12 The + / + genotype was found in 235/254 international controls was found, giving a frequency of 9.2% (95% Cl 8.1 % -10.4%) {Figure 1). O nly the Italian control group6 had a significantly higher prevalence of this common muta tion than the com bined international control group. 
Discussion
The present data confirm our previous observations1 7 2 that the 6 7 7 C^T mutation in the MTHFR gene is a The 677C-*T mutation analysis of all control groups known to us revealed few significant differences in population-specific frequencies; only one Italian study recorded a frequency that was signific antly different from most, but not all, other control groups. The prevalences of the mutation among all different reported NTD patients and their parents were not significantly different between the studies.1'3,4,6'8 C om bining all international data on control groups and families with SB offspring, resulted in a tw ofold increased risk of the mutation for NTD. This increased risk was not only associated with the genotype of the mother but also with that of her child, and thus by implication the genotype of the father.
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In conclusion, the observed frequencies of the 677C->T mutation in the MTHFR gene in the differ ent control groups are w ithin the same range, except for one Italian study.6 Large numbers of controls and NTD families are required for a reliable estimate of the prevalence of this mutation. From this meta analysis we conclude that homozygosity for this com m on mutation results in a twofold increased risk of NTD.
